CD274 and colorectal carcinoma: Preliminary data from microsatellite stable (MSS)-CRC patients who do not typically respond to anti-PD-1/PD-L1-based therapy showed the clinical efficacy and safety of the combination of Monalizumab and Durvalumab (an anti-PD-L1 mAb) [160,161].